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Abstract
Background: The biopharmaceutical industry requires cell lines to have an optimal proliferation rate and a high
integral viable cell number resulting in a maximum volumetric recombinant protein product titre. Nutrient feeding
has been shown to boost cell number and productivity in fed-batch culture, but cell line engineering is another
route one may take to increase these parameters in the bioreactor. The use of CHO-K1 cells with a c-myc plasmid
allowing for over-expressing c-Myc (designated cMycCHO) gives a higher integral viable cell number. In this study
the differential protein expression in cMycCHO is investigated using two-dimensional gel electrophoresis (2-DE)
followed by image analysis to determine the extent of the effect c-Myc has on the cell and the proteins involved
to give the new phenotype.
Results: Over 100 proteins that were differentially expressed in cMycCHO cells were detected with high statistical
confidence, of which 41 were subsequently identified by tandem mass spectrometry (LC-MS/MS). Further analysis
revealed proteins involved in a variety of pathways. Some examples of changes in protein expression include: an
increase in nucleolin, involved in proliferation and known to aid in stabilising anti-apoptotic protein mRNA levels,
the cytoskeleton and mitochondrial morphology (vimentin), protein biosysnthesis (eIF6) and energy metabolism
(ATP synthetase), and a decreased regulation of all proteins, indentified, involved in matrix and cell to cell
adhesion.
Conclusion: These results indicate several proteins involved in proliferation and adhesion that could be useful for
future approaches to improve proliferation and decrease adhesion of CHO cell lines which are difficult to adapt to
suspension culture.
Background
Chinese hamster ovary cells (CHO) are the most popu-
lar commercial platform for the production of therapeu-
tic proteins with much development going into the use
of such cell lines for increasing product yields. Hence
the productivity of cell cultures has improved more than
100-fold in the last two decades mainly due to develop-
ments of fed-batch culture systems, media and process
optimisations in conjunction with expression technolo-
gies [1,2]. As much as improvements in specific produc-
tivity (Qp) are important in cell lines, growth
characteristics also have a significant impact on the pro-
cess. A good cell line proliferative capacity and a high
integral viable cell number( I V C )c a nr e s u l ti nh i g h
volumetric recombinant protein production rates. Thus
the mammalian biopharmaceutical industry has research
interests directed towards the development of cell lines
with high proliferation rate that can be grown to high
densities and have high production capabilities. Induc-
tion of the transcription factor Myc promotes cell prolif-
eration and transformation by activating growth
promoting genes or by repressing the expression of
growth arrest genes [3-11]. The gene, c-myc,i sap r i m e
candidate that regulates cell proliferation in such a way
that its introduction into cell lines may be advantageous.
Research has shown that transfection of adherent
CHO cell line with the c-myc gene resulted in increased
proliferation rate and cell number [11,12]. To under-
stand the cellular activity that results from the overex-
p r e s s i o no fc - M y c( v i at h etransfection with c-myc
plasmid) in CHO cells, the techniques of two-dimen-
sional polyacrylamide gel electrophoresis (2-DE) and sta-
tistically viable image analysis combined with mass
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teins involved. This technique allows for the separation
of complex protein mixtures with a relative high resolu-
tion involving a two-step separation of the proteins, first
by isoelectric point and then by size to generate protein
maps of the investigated proteome.
Currently, the database of the proteomes of CHO cell
is not complete, but due to similarities of mammalian
proteins between species successful identification of pro-
teins can be done across species [13]. This has made it
possible to carry out several proteomic studies on the
CHO cells including a general proteome map [14,15].
Further analysis of the protein regulation under con-
trolled conditions has led to the 2D proteome analysis
of CHO cells in response to hyperosmotic conditions
[16], increased production levels[17,18], low temperature
shift [19], and growth factor stimulation [20]. Also the
proteomic work carried out on c-Myc is limited, not in
CHO cells, and none has been done using the 2DE
approach[21,22] In this study, it is the objective to iden-
tify potential proteins involved in producing the pheno-
type seen with a c-myc plasmid in CHO cells in the
hope of increasing our understanding of the intracellular
and physiological changes and providing further insights
into possible CHO cell manipulation for improved cell
line development. In this work the cell line containing
c-myc plasmid is compared to the parental cell line to
determine if any bioprocessing benefit would have been
achieved. It may be useful to state that a comparison of
the cells containing the c-myc plasmid with cells con-
taining blank plasmid would provide further specific
information on the c-myc effects.
Methods
Cell Transfection and Maintenance
The transfection and selection protocol has been pre-
viously reported [12]. Briefly, the cMycCHO (c-myc
plasmid containing CHO-K1) cell line resulted by cal-
cium-mediated stable transfection of CHO-K1, with the
DORclaG123 (c-Myc plasmid). The plasmid was kindly
donated by Dr. T. Littlewood (then at Imperial Cancer
Research Fund, UK). Surviving cells were pooled sepa-
rately from each transfection and maintained in Ham’s
F12 supplemented with 5% FCS. Dilution cloning was
used to select a stable cMycCHO clone with high over
expression of the c-myc gene for subsequent experi-
ments. Selection pressure was maintained by incubation
in DMEM/F12 with 5% FBS (Lonza Biologics) and 1
mg/mL geneticin G418 (Sigma Aldrich, UK) every 10
th
generation. Samples were taken before and after incuba-
tion to ensure stable overexpression of the c-Myc pro-
tein. To negate the effects of the antibiotic selection
pressure was removed 2 passages before an experimental
run.
Static Batch Culture of CHO-K1 and cMycCHO
In subsequent experiments CHO-K1 and cMycCHO
were maintained in DMEM/F12 with 5% FBS (Lonza
Biologics, UK) at 37°C vented in 5% CO2 incubator. Sta-
t i cc u l t u r e sf r o me a c hc e l ll i n ew e r ep l a t e di n2 5c m
2
(75 cm
2 for proteome isolation) vented T-flasks with an
initial density of 2 × 10
5 cells/ml allowing triplicate
flasks to be sacrificed at regular intervals for each cell
line. Viable cell concentration and viability were moni-
tored using the trypan blue exclusion method [23]. The
sample for proteomic analysis was taken at late expo-
nential phase of the culture. This point also put empha-
sis on that in a limited nutrient environment the
cMycCHO can maintain a higher cell density. To verify
the inoculum had c-Myc over expression a separate
duplicate culture was run for Western analysis.
Determination of Extracellular Glucose and Lactate
Glucose was measured with an Ascencia contour (Bayer
Diagnostics, Ireland) glucose meter using pre-calibrated
Mircofill test strips (Bayer Diagnostics, Ireland). Lactate
was measured using the Accutrend Lactate Meter
together with BM-Lactate Strips (Roche Diagnostics
GmbH, Germany). Briefly, The BM-Lactate calibration
strip was used to calibrate the instrument to the accom-
panied BM-Lactate strips. Lactate was determined by
reflectance photometry at a wave length of 657 nm via a
colorimetric-oxidase mediator reaction.
Proteome Isolation
The experimental setup is illustrated in Figure 1. A
minimum of 1 × 10
7 cells of each replicate was used to
obtain total cellular protein which was washed in iso-
tonic (0.35 M) sucrose to reduce salt contamination and
then resuspended in 400 μl of lysis buffer (Ultrapure
reagents from GE Healthcare, Uppsala, Sweden): 2% (w/
v) CHAPS, 9.5 M urea, 0.8% (w/v) Pharmalyte pH 3-10,
1% (w/v) DTT (GE Healthcare) and 1 protease inhibitor
tablet per 10 ml (Roche Molecular, Mannheim, Ger-
many) for 30 minutes. The cells where then centrifuged
at 4°C and 17,000 g for 30 minutes. Samples were stored
at -80°C for minimum of 24 hours before concentration
determination using a modified Bradford assay [24].
Two-Dimensional Sodium Polyacrylamide Gel
Electrophoresis (2-DE)
An amount of 100 ug protein/gel was used for analytical
gels and 400 ug protein/gel for preparative gels. Lysed
samples were diluted in rehydration buffer (8 M urea,
0.5% [w/v] CHAPS, 0.2% [w/v] DTT, 0.2% [w/v] Phar-
malyte pH 3-10); and the appropriate protein load
applied to each 24 cm, linear pH 4-7, immobilized pH
gradient (IPG) strip (GE Healthcare, Uppsala, Sweden)
by in-gel rehydration [25-27]. IPG strips were focused at
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( 1 )7 5 , 0 0 0V o l t - h o u r s( V h )a t3 5 0 0V ,f o l l o w e db y( 2 )a
gradient increase to 8000 V for 10 min, which was then
left at (3) 8000 V for 1 hour, followed by, (4) 100 V for
a maximum of 3 hours using an IPGphor System (GE
Heathcare). Subsequently, the IPG strips were once
equilibrated in a buffer containing 6 M Urea, 50 mM
TrisCl pH 8.8, 30% (v/v) glycerol, 2% (w/v) SDS and 1%
(w/v) DTT for 15 min and then in the same buffer but
with the addition of 4.8% (w/v) iodacetamide for a
further 15 min. Proteins were separated in the second
dimension by SDS-PAGE (gel format 24 × 20 × 0.15 cm).
After gel fixation in methanol/acetic acid solution, the
analytical gels were stained with 2D-Silver Stain II
Kit (Daiichi Pure Chemicals, Tokyo, Japan) while the
preparative gels were stained with the PlusOne™ Silver
Staining Kit (GE Healthcare) using a modified, mass
spectrometry compatible protocol [28].
Image and Data Analysis
2-D gel images were captured using a Molecular Imager
GS-800 scanner (Bio-Rad), warped with TT900 S2S soft-
ware (Nonlinear Dynamics, Newcastle, UK) and quanti-
tatively analysed using Progenesis PG240 SameSpot™
software (Nonlinear Dynamics, Newcastle upon Tyne,
UK). Protein spot detection and normalization (an inte-
gration of the area and optical density, as a percentage
of the total volume of all detected spots) was performed
automatically, followed by manual checking of detected
spots; reassigning a numerical spot designation and
removing background noise before renormalization and
applying the SameSpot™ analysis algorithm (SSAA). This
Figure 1 Experimental setup and inverted microscopic image of adherent culture of CHO-K1 and cMycCHO cell lines. The Morphology
of cell lines shows adherent c-Myc over-expression causing morphological changes to the cell with the formation of foci. The experimental
design above demonstrates that from the 3 biological replica culture samples, 3 technical sample replicates from each of these were used in
proteomic image analysis setup.
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to gel while pixel level alignment corrects for positional
variation from gel to gel. The fold change value is calcu-
lated from the mean normalised volumes between
cMycCHO and CHO-K1. All spots were compared to
control reference gel and for eliminating experimental
discrepancies between spots. SSAA applies the same
spot outline to corresponding spots for all gels before
the application of ANOVA (p < 0.05) for statistically sig-
nificant changes in their protein expression based on the
normalized volume of each spot. Further ontology analy-
sis was carried out by transferring the Progenesis data to
GenePilot™ V1.95b (TG Services, Inc. CA USA).
LC-MS/MS and Data Analysis
Manual excision of the protein spots of interest and
tryptic digestion were carried out using an Ettan Diges-
ter (GE Healthcare, Uppsala, Sweden) and peptide analy-
sis was carried out using a linear ion trap mass
spectrometer (LTQ Mass Spectrometer; Thermo-Finni-
gan Ltd, Hemel Hempstead, UK). The mass spectra
parameters were set to a full scan MS mass range of
400-1600 m/z. The mass spectrometer was equipped
with a nanospray ion source (Thermo Electron Corpora-
tion, Waltham, MA) with a spray voltage of 1.9 kV. Bio-
Works 3.2 software (Thermo Electron Corporation),
featuring the TurboSEQUEST search algorithm, was
used to query the Swiss-Prot database for protein identi-
fication. Two filters were used to consider significant
hits, peptide Xcorr (statistical criteria correlation value)
versus charge state (charge state: +1, +2, +3; set-points:
1.9, 2.0, 2.5) with a peptide probability-based scoring
algorithm cut-off of < 10
-3.
Western Blot
A protein load of 50 μg/well underwent electrophoresis
on a 12% sodium dodecyl sulfate-polyacrylamide (SDS-
PAGE) mini gel (Pierce, Rockford, IL) subsequent to
dilution in 1× Laemli buffer with prior denaturation at
95°C for 10 minutes. The gel was stained with Instant-
blue™ (Novexin Ltd, UK) for visual verification of load-
ing before de-staining for electrotransfer. The protein
was then transferred to an Immobilon™-P membrane
(0.45 μm) (Millipore, Cork, Ireland) followed by block-
ing of the membranes with 5% Marvel-PBS for 1 hour
at room temperature and probed overnight at 4°C by
incubation with the primary antibody (Santa Cruz Bio-
technology, CA), either anti-myc 9E10, rabbit anti-RKIP,
rabbit anti-NUCL, rabbit anti-eIF6, or rabbit anti-
GRP78. The blot was washed and then incubated with a
HRP conjugated anti-mouse (only for anti-myc) or anti-
rabbit whole IgG as the secondary antibody. Bands were
developed by chemiluminescent detection (SuperSignal
West Pico System, Pierce) according to the
manufacturer’s instructions. Any required blot stripping
was carried out by incubating in NaOH followed by an
overnight blocking in 10% Marvel-PBS at 4°C. The
membranes were stained with Coomassie Brilliant Blue
R-250 (Sigma Aldrich, UK) to re-verify loading and uni-
formity of the electrotransfer.
Results and Discussion
Growth of Cell Lines
For proteomic profiling, a batch culture, in triplicate was
grown (Figure 2) with adherent cMycCHO alongside its
control CHO-K1. The cMycCHO culture had an
increase in overall proliferative capacity being able to
proliferate to higher cell densities of 1.94 × 10
6 cells/ml
compared to 1.14 × 10
6 cells/ml of CHO-K1. The viabi-
lity remained above 90% for both cell lines until day 10
after which CHO-K1 started a steady decline in viability
while cMycCHO culture continued to survive at an
average of 93% on day 16 compared to CHO-K1 which
had a viability of 82%. Under these growth conditions
cMycCHO had an increased growth rate of 0.54 day
-1
compared to 0.48 day
-1 for CHO-K1. The increase in
maximal cell density combined with the increased
growth rate, for an 8 day culture period, resulted in an
IVC increase of 59% for the cMycCHO cell line reach-
ing 10.54 × 10
9 cell day L
-1. Proteomic samples were
taken from where the biggest variation in cell number
was seen between the CHO-K1 and cMycCHO while
still at the highest viability for both cultures and this
was seen to be the late exponential phase.
The increased growth rate had an effect on specific
glucose utilisation and lactate production (Figure 3). In
Figure 3 it can be observed that the glucose and lactate
consumption and production profiles of cMycCHO are
only slightly greater than those of the control. Thus
when calculating these as rates per cell there was a
decrease in the specific glucose rate of 1.72 μmole 10
-6
cells day
-1, for cMycCHO, compared to a rate of 2.15
μmole 10
-6 cells day
-1 for CHO-K1. This shows that the
cMycCHO cell line could be considered more efficient
at glucose utilisation. Similarly, specific Lactate produc-
tion by cMycCHO had decreased by 49.5% in compari-
son to the CHO-K1 value of 4.32 μmole 10
-6 cells day
-1.
These results are in agreement with earlier batch culture
experiments where both glucose utilisation and lactate
production have decreased in the c-myc engineered cell
line [12].
Proteome Profile
The effect of constitutive expression of c-myc plasmid
on the CHO proteome was fairly extensive with initially
more then a 300 proteins deregulated by visual analysis.
Using the Progensis™ statistical package, there were 122
spots detected as being differentially expressed from the
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processing with the tandem MS identification procedure.
From the excised spots, 41 came through the proteo-
mics procedural pipeline passing the identification scor-
ing criteria (Additional file 1; Table S1). Figure 4 shows
the fold change in regulation for these proteins obtained
from the use of Progensis™ image analysis software. The
effect of c-Myc on cellular activity is known to be exten-
sive [7] and thus it is important to try to identify, from
the list of protein hits, which of these proteins may help
confer advantageous phenotypes for cell culture pro-
cesses, by further investigating the molecular functions.
From the protein regulation heat-map, the ontology
using the gene information gives both molecular and
biological function (Figure 5) which provides the initial
indication of the varied functions of the proteins that
are deregulated. To do a fully comprehensive analysis of
the protein pathway system as a whole, the number of
proteins identified would need to be increased. This is
due to a bias introduced towards the identification of
more highly expressed proteins which are seen using 2D
analysis. However, the majority of proteins identified do
give a varied ontology makeup thus they may be used as
an outline for the pathways affected.
From the proteomic data, the majority of proteins iden-
tified can be classified into subcategories of proliferation,
Figure 2 Growth Curve and 2D gel sample points. The growth curve of cMycCHO (clear circles) compared to CHO-K1 (Black circles). This
culture seeded and grown (n = 3) in parallel, cMycCHO (maximum cell density 1.9 × 10
6 cells/ml) has an increased proliferation capacity
compared to the CHO-K1 (maximum cell density 1.1 × 10
6 cells/ml). The proteomic sampling was done at the late exponential phase to analyse
the different proteins involved in developing this phenotype to produce (a) the representative proteome map of cMycCHO from 2D SDS-PAGE
image scan and (b) the representative proteome map of CHO-K1 from 2D SDS-PAGE image scan from loading 100 μg of protein per gel. In
visual comparisons, it can be recognised that the cMycCHO proteome map shows an overall increase in up-regulated protein expression due to
cMyc activity at the late exponential phase of culture. The western (c) indicates a duplicate culture run with the inoculum to verify c-Myc over-
expression.
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sion, protein folding and cytoskeleton although it must
be noted that some proteins have multi-functionality
and will cross over into other cell signaling pathways
such as Nucleolin (NUCL), 60 kDa heat shock protein
(HSPD1), and Peroxiredoxin 2 (PRDX2), which all have
an additional anti-apoptotic activity. Other proteins
identified may not have a specific classified function(s)
at this time.
Proliferation
The protein, PEBP-1(Phosphatidylethanolamine Binding
Protein), also known as Raf kinase inhibitor protein
(RKIP) is down regulated in the proteome profile, con-
firmed by the western blot (Figure 6). It has been impli-
cated as a direct negative regulator of key signaling
kinases [29] but seems to function rather as a modulator
of the Raf/MEK/ERK kinase signaling cascade rather
than an off-switch while its ability to bind nucleotides
and opiods mean it may also have other functions [30].
One important fact remains, that its down regulation
has implications on mitosis where RKIP depletion and
as a result, Raf-1 up-regulation, causes cells to mover
faster through mitosis. Its down-regulation has further
implications on cancer progression and survival [31,32].
In the case of cMycCHO, RKIP depletion, may help
increase the proliferation potential of the cell without
the use of growth factors since the Raf/MEK/ERK cas-
cade is known to be stimulated by growth factors [33].
Recently it was shown that ovarian cancer cells undergo
growth factor stimulated growth by Raf-1 [34] which is
regulated by RKIP [35].
One identified protein of interest is nucleolin (NUCL),
which, like c-myc, is a multifunctional protein with
increased expression in exponentially growing cells and
is found mainly in the nucleolus, at the dense fibrillar
granular regions [36,37]. NUCL has recently been dis-
covered to be a direct target of c-myc [22,38], confirm-
ing the proteomic results for this protein both in the 2D
analysis and the western blot analysis (Figure 6). NUCL
is known to be involved in ribosome biogenesis, mRNA
stabilisation, regulation of transcription, chromatin
decondensation and nucleocytoplasmic transport [39].
What is of additional interest is that it has been shown
to have anti-apoptotic activity. This process is accom-
plished by stabilising bcl-2 and bcl-XL at the mRNA level
[40-43].
Protein Biosynthesis
The protein biosynthesis machinery is a complex system
of protein-protein, protein-DNA, and protein-RNA
interactions. The majority of proteins involved in trans-
lational activity were down regulated. For instance, elon-
gation factor 2 was down regulated. This translational
elongation factor promotes the GTP-dependent translo-
cation of the nascent protein chain from the A-site to
the P-site of the ribosome and ensures high accuracy
and speed of the translational mechanism [44]. As an
extra note, this protein was also selected for western
verification but the rat antibody did not recognize the
CHO protein. In addition, both tryptophanyl tRNA
synthtase and heterogeneous nuclear ribonucleoprotein
(hnRNP A3) are down regulated in cMycCHO. Trypto-
phanyl tRNA synthtase is involved in catalysing the
attachment of an amino acid to the elongation factor 2
cognate transfer RNA molecule and hnRNP A3 impli-
cated in cytoplasmic RNA trafficking [45-47].
Two other proteins involved in protein biosynthesis
were up-regulated. Firstly, Translation Factor eIF6, also
demonstrated in the western blot (Figure 6), which can
regulate translation by modulating the access of the
large ribosomal subunits to the elongation cycle, binds
to 60S subunits which are activated by release of eIF6
[48]. Overexpression of eIF6 overloads 60S subunits
with eIF6 resulting in a dose-dependent inactivation of
translational activity and blocking 80S formation [49].
Additionally, eIF6 is required for miRNA silencing of
translation [50]. The second up-regulated protein is
initiation factor 4A-II (eif4A2), a protein which allows
efficient binding of the small ribosomal subunit, and
subsequent scanning for the initiator codon and comes
from a family that participates in diverse processes apart
from translation, including pre-mRNA splicing and ribo-
some biogenesis [51,52]. Using what has been found
about the physiology of CHO cells it could be postu-
lated that this decrease in translational machinery can
Figure 3 Glucose utilization and lactate production.F o rt h e
cMycCHO culture, glucose utilisation is represented by a solid line
with a black circle and a solid line with clear circle for CHO-K1. For
lactate measurements, taken from the extracellular environment, the
cMycCHO culture is represented by a dashed line with black upside
down triangles and CHO-K1 is indicated with a dashed line with
clear upside down triangles. Both cultures show a similar profile but
differ in specific utilisation and production.
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It already has been put forward that the regulator of cell
size, the mTOR pathway, is directly involved in transla-
tion control and that the main factors involved in
recruiting the ribosome are phosphoproteins whose
phosphorylation states are modulated by mTOR path-
way proteins [53]. Also, it was shown that the CHO-K1
cell line has a decreased critical mass for initiating entry
into S phase of the cell cycle (unpublished data).
Energy Metabolism
In terms of energy metabolism the proteins ATP synthe-
tase subunit beta and alpha chain which are involved in
ATP synthesis have been up-regulated in cMycCHO.
These proteins are part of the ATP synthetase complex
providing the primary utilizable high energy phosphate
bonds in the form of adenosine triphosphate (ATP) for
numerous cell processes, acting as an allosteric effector
[54]. This could indicate a change in the glycolytic path-
way to release more ATP, a possibility supported by
similar changes in phosphoglycerate kinase activity
which plays a predominant role in the conversion of 3-
phosphoglyceroyl phosphate into 3-phosphoglycerate to
make ADP into ATP [55]. Pyruvate kinase isozymes
M1/M2 (highly active tetrameric form/nearly inactive
dimeric form) was up-regulated and this gycolytic
enzyme catalyzes the transfer of a phosphoryl group
from phosphoenolpyruvate (PEP) to ADP, (subsequently
generating ATP) [56] which corresponds with the up-
regulation of ATP synthetase subunit beta and alpha
Figure 4 Barchart of MS/MS identified proteins illustrating preliminary identification of proteins and their corresponding fold changes
with a p-value above 0.05.
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tion between the 2 isozyme forms contributes to the
control of glycolysis [57]. Spoden et al, found that M2-
PK can act under reduced glucose consumption leading
to enhanced cell cycle progression as well as survival,
while reducing cell size[58], an observation seen with
this cell line. Another up-regulated protein is isocitrate
dehydrogenase (IDH), which participates in the tricar-
boxylic acid cycle, and is found to contribute overall to
glutamate synthesis, cellular growth from carbon
sources and to mtDNA stability [59,60].
The fact that cMycCHO cell line has decreased lactic
acid production is likely the resultant from the down
regulated lactate dehydrogenase (LDH) activity. Lactate
dehydrogenase catalyses the interconversion of pyruvate
and lactate and the suppression of LDH in CHO cells
have consequently resulted in increased ATP synthesis
[61]. In addition, efficient shuttling of pyruvate into the
citric acid cycle which can be responsible for decreased
lactate production as well. An interesting note is that
specific glucose consumption is slightly lower in cMyc-
CHO. This can be related to the protein Triose-phos-
phate isomerase being down regulated as a main
glycoltyic protein involved in glucose processing in the
pathway and increased dimeric M2-PK activity. There
was a 50% decrease in lactate production in cMycCHO
culture indicating that there could be improved utilisa-
tion of glucose to increase ATP output due to aerobic
glycolysis being more efficient.
Cellular Adhesion
Proteins involved in promoting cellular adhesion were
all down-regulated in the cMyCHO cell line. One of the
down-regulated protein is integrin beta 2 precursor, a
protein involved in the integrin mediated pathway with
a main functional role in cell to cell adhesion [62]. The
integrin beta 2 precursor, although passing the identifi-
cation criteria set, did not score high, with a cross
Figure 5 The Heatmap illustrates the hierarchical clustering found in the replicate profile differentiating the two cell lines for the set
of identified proteins found in the protein expression and the associated ontology of the proteins. The value range is defined by the
minimum and maximum values in the entire dataset with zero being the medium value. The row dendigram displays the cluster of the
proteome replicates with similar rows clustered together. Distances can be roughly determined by the height of the node that binds the
replicates together, all technical replicates were found to be alongside each other making the start of each biological replicate 1
st,4
th,7
th in line.
One replicate in the CHO-K1 dataset showed the most variation from the dataset but was still within the CHO-K1 node. The ontology indicated
that the c-Myc had affected a large range of molecular pathways and from the identified dataset blue indicates cellular processes affected and
red indicates molecular function affected.
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was supported by the presence of other down regulated
proteins involved in adhesion which was seen to be con-
sistent throughout the analysis. Another protein which
is down-regulated and known to promote cell adhesion
is Galectin-1 (Gal-1). This protein has been shown to
increase the adhesion of various cell lines to the extra
cellular matrix (ECM) through crosslinking the integrins
with ECM components such as laminin and fibronectin
[63-65]. Gal-1 also causes the biphasic modulation of
cell growth [66,67]. The down-regulated annexin-A2
(ANX2, formerly called annexin II), is a protein encoded
by some 20 different genes and promotes enhanced cell
to cell adhesion when expressed on the surface of meta-
static cells [68]. This protein has multi-functionality
since it is shown to be associated with cell-matrix inter-
action and been suggested to have a role in exocytosis
and endocytosis [69]. Early work has briefly looked at
the attachment and detachment properties of cMycCHO
showing that the cell line was only able to attach 85% of
cells onto a substratum surface as a monolayer while
the control attached 100% of cells after 200 minutes,
while cell detachment rate was shown to be faster than
the control [12].
Another protein that has been shown to affect the adhe-
sion of the cell is Calreticulin (CRT). This multifunctional
protein is also known to be involved in endoplasmic reti-
culum (ER) associated pathways but when expressed on
the cell surface it can modulate the adhesion properties
where it has been reported to complex with integrins
[70,71]. Furthermore it is able to bind to laminin [72] and
fibrinogen [73], which would explain why CRT down reg-
ulation is associated with weaker attachment of the cMyc-
CHO cell line to both of these surface proteins[72,73].
CRT has also been shown to regulate vinculin (a cytoske-
letal protein involved in adhesion) in fibroblast cells where
its overexpression increased cell to cell adhesion and cell
substratum adhesion [74].
Earlier [12] and current work on CHO cell adhesion
(data not shown),) together with this proteomic
Figure 6 Immunoblot validation of identified protein spots. A western analysis of biological triplicate samples with c-Myc over-expression
observed in the cMycCHO cell lines validated the observed proteomic results. The membranes were stained with Coomassie brilliant blue to
re-verify loading and uniformity of the electro-transfer after band detection, due to c-myc de-regulating both cytoskeleton and metabolic proteins.
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teins were found to impart the less adhesive phenotype
may be further studied to reengineer cell lines with even
greater suspension culture adaptation efficiency or to
stop the reversion of cell lines to adherent culture as
this is the case with many CHO cell lines.
Cytoskeleton
Several proteins related to cytoskeletal activity were
de-regulated in the cMycCHO cell line, such as tropo-
myosin which is involved in binding actin affecting the
assembly and disassembly of actin filaments but its
exact mechanism still remains to be determined [75].
Tropomyosin has several isoforms that are cell cycle
dependant [76,77]. This relationship with the cell cycle
could explain the up-regulation of the protein within
the cMycCHO cell line. A cytoskeletal associated pro-
tein that recently has been implicated in cell and mito-
chondrial morphology plus organisation is vimentin.
This protein has been suggested to be the intermediate
between the mitochondria and microtubules and its
depletion results in mitochondrial reorganization and
defragmentation [78]. The up-regulation of the dynami-
cally structured vimentin could be related to the up-reg-
u l a t i o no fp r o t e i n si n v o l v e di nA T Pa n dg l u c o s e
processing discussed earlier, but further studies into the
role of this protein and its interaction with the mito-
chondria will need to be investigated in order to come
to a firm conclusion. In previous proteomic studies of
CHO cells, vimentin was shown to be up-regulated
when the cells where temperature shifted to a lower
temperature to induce increased protein secretion rates
but decrease cell cycle kinetics [79,80], although the
cells seemed to be at a resting state arrested in G0/G1
of the cell cycle, in both cases the proteins related to
metabolic energy production pathways were up-regu-
lated and studies involving glucose consumption mea-
surements at lower temperatures confirm these results
in CHO cells [81]. This further supports a possible role
of vimentin in determining the metabolic state of the
cell.
Another cytoskeletal protein, which has been investi-
gated for its role in secretory vesicle transport is F-actin
capping protein [82]. F-actin capping protein regulates
growth of the actin filament by capping the ends of
growing filaments. It is involved in exocytosis of the cell
by negatively regulating exocytosis via binding and
blocking Syntaxin 4 accessibility [82]. The over-expres-
sion of F-actin capping protein has been shown to
increase protein secretion [18]. Another proteomic
study found that this protein is down regulated 1.5 fold
at 37°C after 144 hours but not at 31°C [80], but since
these results where in a non-productive cell line the
affect this has on productivity could not be concluded.
In cMycCHO, F-actin capping protein is also down-
regulated giving the possibility that c-Myc overexpres-
sion may divert secretory cellular machinery to decrease
protein secretion.
Protein folding
As mentioned before CRT is also involved in the ER pro-
cessing pathways in addition to its role in cell adhesion
processes. CRT is known to function as a molecular Ca
2+
binding/storage chaperone involved in the folding of pro-
teins and glycoproteins [83]. It normally resides in the ER
lumen where it binds to mis-folded proteins and prevents
them from being exported from the ER to the Golgi
apparatus. It has been shown, using fluorescently labeled
proteins, that calreticulin interacts with protein disulfide
isomerase (PDI) in a Ca
2+-dependent manner [84]. As it
happens PDI is also down regulated in cMycCHO cells
along with another ER protein; endoplasmin precursor
(GRP94). The other identified ER protein was GRP78,
which was found to be up-regulated, both in the 2D ana-
lysis (Figures 4 and 5) and western detection assay (Fig-
ure 6). The ER lumenal molecular chaperones known to
be involved in monoclonal antibody synthesis and assem-
bly are PDI, GRP94, and GRP78 [85]. The effect this has
on protein secretion has been shown to be cell type and
protein specific [86-89]. This might indicate that cMyc
has an effect on the productivity, but it must not be ruled
out that it may be dependent on the type of protein
secreted as well, and thus further investigation would be
needed to address this particular question. Thioredoxin
was found to be down regulated, and since this protein is
known to reduce disulfide bonds in target protein it may
affect protein production/secretion rates. Thioredoxin is
also involved in DNA synthesis as a hydrogen donor for
ribonucleotide reductase [90]. Since cell division has
increased for the cMycCHO cell line, it is likely that a
reduction in protein folding could, partly, be due to
down-regulated thioredoxin in the cytoplasm, meaning
less thioredoxin is available for this particular, process
rather then the thioredoxin associated with DNA synth-
esis. A future study using cellular fractionation might
give further insight into the function of this protein in
the folding pathway.
Another protein involved in protein folding is the 60
kDA heat shock protein (HSP60) which was found to be
up-regulated. This is a mitochondrial chaperone respon-
sible for the transportation and refolding of proteins
from the cytoplasm into the mitochondrial matrix [91].
Since mitochondrial associated proteins that have been
identified related to increases in energy production are
up-regulated it might explain the increase in HSP60 to
help the mitochondrial function optimally. HSP60 may
also play a key role in anti-apoptotic activity by binding
to BAX and Bak [92]. Another anti-apoptotic
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p r o t e o m ep r o f i l ei sP R D X 2 .T h i si sa na n t i o x i d a n t
enzyme that uses its cysteine residues to breakdown
reactive oxygen species (ROS) and found to have cha-
perone activity as well, when the cell is under stressful
conditions [93]. A reduced PRDX2 has limited capacity
to eliminate ROS but a chaperone activity becomes
more prominent at this stage [94]. To survive at higher
cell densities than the control, cMycCHO must be able
to augment its internal machinery to prevent apoptosis
occurring while growth takes place beyond the control
cell line. The increase in PRDX2 and HSP60 activity
both relate to cell survival and HSP60, additionally sup-
ports the mitochondrial proteins to work efficiently by
being a mitochondrial chaperone.
A protein also known to affect apoptotic pathways is
Cytochrome C, which was down-regulated in cMycCHO
culture. This protein is known for sensitizing the cell
towards the mitochondrial activated pathway for apop-
tosis and could help explain why the cMycCHO cell
appeared to have a longer stationary phase culture (with
viability above 90%).
Conclusion
The present study has identified several proteins in an
enhanced-proliferation cell line with increased maximal
cell density that can relate to the phenotype that may be
used as future targets in CHO cell engineering strate-
gies. Changes in proteins involved in energy metabolism
appear to be related to the increased cell density. Also,
the decreased lactate production can be explained by
the down regulation of LDH. Moreover, this study gives
further insights into the mechanism related to the down
regulation of adhesion proteins by c-Myc that may form
the bases for developing an anchorage independent
CHO cell lines.
Additional file 1: Table S1 displaying protein species with a
changed regulation for cMycCHO. A list of protein species with a
changed regulation level for cMycCHO versus the CHO-K1 control cell
line. XCorr Score is an abbreviation for the raw cross-correlation score of
the top candidate peptide or protein for a given input data file. The
higher the XCorr Score, the better the match to the searched sequence
at a probability cut off (P > 0.001). Note that Xcorr values in combination
with the search parameters rather than the matched peptides should be
considered as significant hits.
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